Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the H.C. Wainwright 2 nd Annual BioConnect Conference on Monday, May 20, 2024, at 12:30 p.m. ET.

The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

About Acumen Pharmaceuticals, Inc.

Acumen, headquartered in Charlottesville, VA, with additional offices in Indianapolis, IN and Newton, MA, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD). Acumen's scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, following positive results in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer's disease patients. For more information, visit www.acumenpharm.com .

Investors:
Alex Braun
abraun@acumenpharm.com

Media:
AcumenPR@westwicke.com



Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ABOS:US
The Conversation (0)

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

  • Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in May 2024

  • Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024

  • Cash, cash equivalents and marketable securities of $296.6 million as of Mar. 31, 2024, expected to support current clinical and operational activities into the first half of 2027

  • Company to host conference call and webcast today at 8:00 a.m. ET

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the first quarter of 2024 and provided a business update.

"In the first quarter, our team remained laser-focused on the initiation of ALTITUDE-AD, our Phase 2 study investigating the efficacy and safety of sabirnetug for the treatment of early AD. We announced the first patient dosed in this study just last week. We are encouraged by the level of investigator interest in the potential of sabirnetug to offer a best-in-class therapeutic profile for patients, which is a testament to our strong Phase 1 data package and the relationships our team has built with clinical sites," Daniel O'Connell, Chief Executive Officer of Acumen. "We continue to expect to initiate a Phase 1 study with a subcutaneous form of sabirnetug in mid-2024 in an effort to extend the product profile and offer administration optionality for patients. We remain committed to delivering on our strategic priority to advance the clinical development of sabirnetug efficiently and thoughtfully."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024, at 8:55 a.m. PT (11:55 a.m. ET).

The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug in Early Alzheimer's Disease

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the first patient has been dosed with sabirnetug (ACU193) in the ALTITUDE-AD Phase 2 clinical trial designed to evaluate the clinical efficacy and safety of sabirnetug in patients with early AD.

"Today marks a significant milestone for Acumen and the Alzheimer's community as we begin the Phase 2 trial of sabirnetug," said Daniel O'Connell, Chief Executive Officer of Acumen. "Sabirnetug is at the forefront of the next generation of Alzheimer's therapies, with encouraging Phase 1 results supporting its novel mechanism of action and selectivity for toxic amyloid beta oligomers. These results have led to a high level of investigator and patient interest in sabirnetug's therapeutic potential and a strong start to the trial."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report first quarter 2024 financial results on Tuesday, May 14, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

To participate in the live conference call, please register using this link . After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
FPX Nickel Completes Additional Large-Scale Mineral Processing Pilot Testwork to Produce Awaruite Concentrate to Support Discussions with Prospective EV Battery Supply Chain Partners

FPX Nickel Completes Additional Large-Scale Mineral Processing Pilot Testwork to Produce Awaruite Concentrate to Support Discussions with Prospective EV Battery Supply Chain Partners

FPX Nickel Corp. (TSXV: FPX), (OTCQB: FPOCF) (" FPX " or the " Company ") is pleased to announce that it has successfully completed another large-scale mineral processing pilot testing campaign for the Baptiste Nickel Project (" Baptiste " or the " Project "). Building on the success of three previous pilot testing campaigns, a production run was completed to produce bulk samples of awaruite concentrate which will be used to verify the suitability of using this concentrate as a feedstock in third-party nickel refineries. Samples will be provided to selected prospective downstream partners — most notably pCAM producers, battery companies, and automakers — who typically secure nickel units directly and contract refiners to process feedstocks on their behalf. This reflects an established industry model, supporting end users' pursuit of supply security, traceable sourcing, and low-carbon production.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Silver47 Highlights Expansive High-Grade Gold and Silver System at the Kennedy Project, Nevada

Silver47 Highlights Expansive High-Grade Gold and Silver System at the Kennedy Project, Nevada

Samples up to 44.5 g/t Gold, 3,037 g/t Silver, and 8.56% Copper

Silver47 Exploration Corp. (TSXV: AGA,OTC:AAGAF) (OTCQB: AAGAF) ("Silver47" or the "Company") is pleased to provide assay results from a recently completed rock sampling program at its high-grade Kennedy gold-silver Project in Nevada (the "Kennedy Project"). Results demonstrate strong prospectivity for high-grade gold and silver mineralization across the under-explored project.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Osisko Intersects 1117.5 Metres Averaging 0.25% Cu at Gaspé

Osisko Intersects 1117.5 Metres Averaging 0.25% Cu at Gaspé

Osisko Metals Incorporated (the " Company or " Osisko Metals ") ( TSX: OM,OTC:OMZNF ; OTCQX: OMZNF ; FRANKFURT: 0B51 ) is pleased to announce new drill results from the Gaspé Copper Project, located in the Gaspé Peninsula of Eastern Québec.

Osisko Metals Chief Executive Officer Robert Wares commented: " Drill hole 30-1097 produced our longest intersection so far, returning 1117 metres of continuous mineralization from the top of Copper Mountain, located in the heart of the deposit. With 10 drills on site, we have completed over 65,000 metres of the drill program to date, and will continue the current program of infill and expansion drilling until December. The updated MRE is well on track to be released in Q1 2026. "

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

Ă—